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The disease complex medullary cystic disease/familial juvenile hyperuricemic nephropathy (MCKD/FJHN) is
characterized by alteration of urinary concentrating ability, frequent hyperuricemia, tubulo-interstitial
ﬁbrosis, cysts at the cortico-medullary junction and renal failure. MCKD/FJHN is caused by mutations of
the gene encoding uromodulin, the most abundant protein in urine. Here, we describe new missense
mutations in three families with MCKD/FJHN and demonstrate allelism with a glomerulocystic kidney disease
(GCKD) variant, showing association of cyst dilatation and collapse of glomeruli with some clinical features
similar to MCKD/FJHN as hyperuricemia and impairment of urine concentrating ability. Furthermore, we
provide the ﬁrst functional characterization of uromodulin mutations. The four newly identiﬁed mutants were
characterized by immunoﬂuorescence and FACS analysis on transfected cells. These experiments showed
that all uromodulin mutations cause a delay in protein export to the plasma membrane due to a longer
retention time in the endoplasmic reticulum. Immunohistochemistry on GCKD and MCKD/FJHN kidney
biopsies revealed dense intracellular accumulation of uromodulin in tubular epithelia of the thick ascending
limb of Henle’s loop. Electron microscopy demonstrated accumulation of dense ﬁbrillar material within the
endoplasmic reticulum. Consistently, patient urines show a severe reduction of excreted uromodulin. The
maturation impairment is consistent with the clinical ﬁndings and suggests a pathogenetic mechanism
leading to these kidney diseases.
INTRODUCTION
Glomerulocystic kidney disease (GCKD) and medullary cystic
disease/familial juvenile hyperuricemic nephropathy (MCKD/
FJHN) are two distinct renal disorders that share some common
clinical features. The former is characterized by a cystic
dilatation of Bowman’s space and a collapse of glomerular tuft.
Familial GCKD can be associated with either hypoplastic or
normal sized kidneys. A GCKD clinical variant presents the
association with hyperuricemia due to low fractional excretion
of uric acid and severe impairment of urine concentrating
ability that are reminiscent of MCKD/FJHN (1).
MCKD is a typical tubulo-interstitial disorder characterized
by alteration of urinary concentration, frequent hyperuricemia,
tubulo-interstitial fibrosis, frequent cysts at the cortico-
medullary junction and renal failure. It is a genetic and clinical
heterogeneous disorder with two known loci on chromosome
1q21 (MCKD1; MIM 174000) (2) and on chromosome 16p12
(MCKD2; MIM 603860) (3). FJHN (MIM 162000) features are
very similar to those seen in MCKD, that is hyperuricemia,
gout, progressive renal failure at an early age, and autosomal-
dominant inheritance. Common critical regions (4–7) raised the
possibility that MCKD and FJHN could arise from mutations
of the same gene. In fact, both diseases were found associated
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to uromodulin mutations (8,9). Uromodulin, also referred to as
Tamm–Horsfall protein, is exclusively expressed by epithelial
cells of the thick ascending limb (TAL) of the loop of Henle
(10) and by distal convoluted tubules (DCT) (11) and is the
most abundant protein in urine. Uromodulin was initially
characterized by Tamm and Horsfall in 1950 (12), but despite
being extensively studied in the past 50 years its function is not
well established. It has been hypothesized to be responsible for
water impermeability of the TAL due to its ability to form a
reversible gel-like structure (13,14) and to modulate the
urothelial defense against infections (15). These putative
functions seem directly correlated with the typical clinical
manifestations of MCKD/FJHN that are alterations of con-
centrating ability and tubulo-interstitial infiltration and fibrosis.
Here we describe new mutations of uromodulin in three Italian
families with MCKD/FJHN and the first reported uromodulin
mutation in a GCKD family. Immunohistochemistry and
electron microscopy on patient kidney biopsy reveal pathologic
evidence of dense intracellular accumulation of this protein in
tubular epithelia of the thick ascending limb of Henle’s loop.
Consistently, the amount of excreted uromodulin is severely
reduced in patients’ urine. Cellular studies with uromodulin
mutants demonstrate impairment of maturation/export
dynamics, thus defining the pathogenetic mechanism leading
to these kidney diseases.
RESULTS
Clinical findings
In this study we performed clinical and genetic analysis of
individuals from three MCKD/FJHN and one GCKD Italian
families (Fig. 1). Clinical features of family MCKD#1 have
been already described (3). The GCKD#1 family included three
affected patients in two generations (1). Patients III-2 and III-3
were two siblings of 40 and 41 years with mild renal
insufficiency and normal or mild polyuria. Both had an
increase of serum uric acid and decreased urine osmolality. The
youngest member (IV-1) was a male of 16 years with
hyperuricemia, slight increase of serum creatinine and
defective urine osmolality. In order to exclude GCKD
associated with maturity-onset diabetes, we performed glucose
tolerance test and HNF-1b (16) sequence analysis, both
resulting negative. Ultrasound evaluations in all patients
demonstrated reduced kidney volumes with cortical hyper-
echogenicity. Renal tissue was available in III-2 and III-3
showing, in both cases, marked dilatation of Bowman’s space
in most glomeruli (about 40%) with reduced or rudimentary
glomerular tufts attached to the capsule. No tubular dilatations
and/or dysplastic elements were found. Diffuse albeit mild
interstitial fibrosis was present. Family MCKD#7 included 47
members, 17 of which presented at least one symptom
characteristic of the disease. All but one (V-2) had reduced
urine osmolality and polyuria. At the time of examination,
seven patients (III-4, III-5, III-12, III-13, III-16, IV-2, IV-15)
presented an association of chronic renal failure (CRF) and
hyperuricemia with or without gout, while hyperuricemia was
isolated in four cases (III-2, III-3, III-19, IV-6) and CRF was
the unique symptom in 4 (III-7, IV-3, IV-11, V-1). In one
patient (V-2) the unique finding was the presence of numerous
renal cysts and finally low urine osmolality was the only
finding in one patient (IV-17). The three-generation Italian
pedigree MCKD#9 included five affected individuals. Three
members (II-2, III-1 and III-2) were available for clinical and
genetic analysis. Individual II-2 had polyuria and nycturia since
infancy and increased serum creatinine and uric acid levels
since age 17. Her mother (I-2) died from severe renal failure.
At the moment of diagnosis the proband creatinine serum level
was 2.6 mg/dl and serum uric acid level was between 8.7 and
9.3 mg/dl. Kidneys were small, without cysts, and with rounded
calices at urography analysis. Proteinuria was absent and urine
sediment analysis was negative. Renal function was progres-
sively impaired and presently at the age of 60 the patient has
started to undergo dialysis treatment. She experienced gouty
attacks that were successfully treated with Allopurinol.
Individuals III-1 and III-2 are respectively 17 and 21 years
old. They show elevated serum creatinine and uric acid levels
with absence of proteinuria and pathologic sediment. They both
have nycturia and small kidneys without cysts.
The main clinical findings of the 28 MCKD/FJHN and three
GCKD patients are shown in Table 1. Despite a remarkable
inter- and intra-familial variability, two clinical signs seem to
be shared by the vast majority of patients. Impairment of urine
concentrating ability, with urine osmolality lower than 800
mOsm (mean urine osmolality was 404.8 156.8 mOsm), was
evident in all but two of the 31 analyzed patients (family
MCKD#1, individual IV-5; family MCKD#7, individual V-2).
Elevated serum level of uric acid is present in all the MCKD/
FJHN and GCKD patients with the exception of patients
IV-11, IV-17, V-1 and V-2 of family MCKD#7. Considering all
affected members, the mean serum uric acid concentration was
8.3 2.3 mg/dl whereas it was 3.7 1 mg/dl in unaffected
relatives. Interestingly, patients from family MCKD#1 seem to
have a milder phenotype. In fact, none of them has developed
CRF and one patient only (II-3) has undergone dialysis
treatment by the age of 60.
Mutational analysis
We performed mutational analysis in the UMOD gene, which
encodes uromodulin, in the three MCKD/FJHN and one
GCKD families described above. All families were either
linked or compatible with linkage to the chromosome 16p12
MCKD2 locus. Family MCKD#1 is the original one that we
analyzed for the linkage mapping of MCKD2 locus (3). Family
MCKD#7 was significantly linked to the same chromosomal
region with Zmax¼ 3.7 (y¼ 0.00) for marker D16S3041.
Families MCKD#9 and GCKD#1 were compatible with
linkage to chromosome 16p12, although not reaching statisti-
cally significant LOD score values.
Direct DNA sequencing of UMOD gene revealed four new
non-conservative missense mutations (Fig. 2) that are listed in
Table 2. We verified cosegregation of the mutations with the
disease haplotypes by direct-sequencing all the family
members and confirmed a complete penetrance, since no
unaffected member carried the disease haplotype and, there-
fore, UMOD mutation. None of the four missense mutations
was found in 200 control chromosomes.
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Uromodulin is a very highly conserved protein showing
approximately the same degree of sequence similarity (77–83%
identities) with its rat, mouse, dog and cow homologs (Fig. 3).
An important feature is the high content of cysteine residues
(48 out of 640 amino acids; 7.5%) that are prevalently
distributed in the N-terminus. All cysteine residues are
conserved in uromodulin mammalian homologs, including
C148, C150, C315 and C317 that we found mutated in MCKD/
FJHN and GCKD patients.
Uromodulin secondary and tertiary structure is not well
established. The representation shown in Figure 4 was obtained
by computer-based analysis with domain/pattern identification
programs and is in agreement with previously reported ones
(17) with exception of an additional EGF-like domain (IV).
Uromodulin mutations C148W, C315R and C317Y hit cysteine
residues that localize in cbEGF-like domains III and IV.
Although cysteine residue 150 is not part of any recognizable
domain, it is probably engaged in intrachain disulfide bond
formation, since the protein monomer does not contain any free
sulfydryl group (18).
Delayed export of uromodulin mutant isoforms
to the plasma membrane
Uromodulin is synthesized as an 84 kDa precursor that is
slowly converted to the mature glycosylated protein with an
apparent molecular weight of 97 kDa. The maturation rate
appears to be dependent on the retention time in the
endoplasmic reticulum (ER) probably because the rate-limiting
step is the formation of the correct set of disulfide bonds in that
compartment (19).
We hypothesized that the MCKD/FJHN and GCKD muta-
tions could hit cysteine residues involved in disulfide bonds
therefore affecting the maturation/export rate of uromodulin.
To assess this hypothesis, we performed transient transfection
experiments using wild-type and mutant constructs in HEK293
and HeLa cell lines that do not express uromodulin. When
transfecting with equal amounts of constructs and with equal
transfection efficiency, as determined by cotransfection with an
EGFP-expressing plasmid, we were able to reveal significant
differences in cells transfected with mutant constructs com-
pared with wild-type ones.
Four hours after transfection the amount of uromodulin that
was exposed on the plasma membrane was significantly
reduced in cells expressing the mutant constructs. This was
evident in immunofluorescence experiments as a marked
reduction of both the number of positive cells and the intensity
of uromodulin staining (Fig. 5). Interestingly, cells expressing
wild-type uromodulin that were cultured in reducing conditions
showed a marked reduction of membrane-exposed uromodulin,
mimicking the mutant phenotype (data not shown).
In order to better define the uromodulin export dynamics, we
performed time-lapse experiments by fixing cells at different
times after transfection (2, 4, 6, 8, 12, 20, 40, 48, 50 and 74 h).
The reduction of the amount of mutant uromodulin signal on
the plasma membrane could be clearly seen up to 8–12 h after
Figure 1. Pedigrees of families MCKD#1, MCKD#7, MCKD#9 and GCKD#1.
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transfection, while it was more difficult to be detected at longer
times. Eventually, mutant cells were similar to wild-type ones
by 48 h after transfection.
We verified that the lower amount of exposed mutant
uromodulin was not due to an overall reduction of protein
amount in the cell due to reduced transcription/translation
efficiency of the mutant constructs. Western blot analysis
showed a comparable uromodulin signal in mutant and wild-
type transfected cells (data not shown).
Different amounts of exposed uromodulin between wild-type
and mutant expressing cells were confirmed by transfections in
HeLa cell line. In this system, the difference between mutants
and wild-type appeared later than in HEK293, i.e. 6–8 h after
transfection. This possibly reflects a difference in the ability of
maturating uromodulin in the two cell types.
Interestingly, we observed a dramatic change of cell
morphology dependent on uromodulin expression. Both cell
types developed several membrane projections that could be
seen both in wild-type and mutant transfected cells. The
membrane projections seemed to be proportional to the amount
of exposed protein and are probably an effect of the increasing
amount of uromodulin that is transferred to the plasma
membrane (Fig. 6).
In order to quantify the number of transfected cells exposing
uromodulin on the plasma membrane we used fluorescent
activated cell sorter (FACS) analysis. In HEK293 cells that were
sorted 14 h after transfection a significant difference could be
seen. When transfecting with mutant isoforms, the number of
uromodulin positive cells was significantly reduced in mutants
C148W, C150S and C315R. The extent of the reduction varied
in the different mutants and ranged from 40% in C148W and
C315R mutants to 60% in C150S mutant. On the contrary,
C317Y isoform showed values that did not significantly differ
from the wild-type (Fig. 7A and B). When simulating the
heterozygote state, the number of uromodulin-positive cells was
between that of wild-type and mutant. Wild-type transfected
cells that were cultured in increasing amounts of DTT showed a
progressive reduction of the number of uromodulin-positive
cells. To further investigate export dynamics of uromodulin
mutants, we sorted cells at 6, 8 and 10 h after transfection.
Interestingly, the number of uromodulin-positive cells trans-
fected with C317Y construct was considerably reduced at 6 h
after transfection and reached values comparable to the wild-
type by 10 h (Fig. 7C).
These results confirm the immunofluorescence findings
showing that the four missense mutations found in MCKD/
FJHN and GCKD patients and affecting cysteines 148, 150,
315 and 317 cause a delay in uromodulin export to the plasma
membrane. Also, C317Y mutation affects export kinetics to a
lower extent with respect to the other cysteine replacements,
Table 1. Clinical and molecular findings in the reported MCKD/FJHN and GCKD families
Family Patient Age at
diagnosis
Morning urinary
osmolality
(mOsm H2O/kg)
Serum
creatinine
(mg/dl)
Serum
uric acid
(mg/dl)
Gout Renal
ultrasound
Uromodulin
change
ADMCKD#1 II-3 54 300 2 12 y SK, MC C317Y
ADMCKD#1 III-4 18 300 1.5 9.6 n SK C317Y
ADMCKD#1 III-5 25 330 1.6 5.9 n SK C317Y
ADMCKD#1 III-7 30 315 1.3 9.2 n SK C317Y
ADMCKD#1 III-10 29 295 1.7 12 y SK C317Y
ADMCKD#1 IV-1 16 310 1.6 5.5 n SK C317Y
ADMCKD#1 IV-5 17 900 0.8 7.5 n NK C317Y
ADMCKD#1 IV-6 18 330 1.5 9.5 n NK C317Y
ADMCKD#7 III-2 50 nd 0.8 8 y nd C150S
ADMCKD#7 III-3 55 nd 0.9 9 y NK C150S
ADMCKD#7 III-4 60 nd 6 10 y SK C150S
ADMCKD#7 III-5 60 nd 8 10 y SK C150S
ADMCKD#7 III-7 65 nd 2.8 7.1 n SK C150S
ADMCKD#7 III-12 50 300 10 11 y SK C150S
ADMCKD#7 III-13 60 320 2.5 12 y SK C150S
ADMCKD#7 III-16 65 400 1.7 8 y SK C150S
ADMCKD#7 III-19 67 nd 0.8 9 y NK nd
ADMCKD#7 IV-2 40 408 2.5 11 y SK C150S
ADMCKD#7 IV-3 45 350 9 7 n SK C150S
ADMCKD#7 IV-6 40 575 0.6 7.4 y NK C150S
ADMCKD#7 IV-11 25 650 1.6 5 n NK, MC C150S
ADMCKD#7 IV-15 40 390 1.5 8 y NK, MC C150S
ADMCKD#7 IV-17 42 729 0.9 4.6 n NK C150S
ADMCKD#7 V-1 21 410 1.4 3 n NK, MC C150S
ADMCKD#7 V-2 28 912 0.4 3.5 n NK, MC C150S
ADMCKD#9 II-2 39 308 2.6 9.2 y SK C148W
ADMCKD#9 III-1 17 319 1.9 8.9 n SK C148W
ADMCKD#9 III-2 21 364 2.1 8.6 n SK C148W
GCKD#1 III-2 12 420 2.3 8 n SK, CC C315R
GCKD#1 III-3 11 380 1.8 9 n SK, CC C315R
GCKD#1 IV-1 9 300 1.3 8.5 n NK, CC C315R
SK, small kidneys; NK, normal kidneys; MC, medullary cysts; CC, cortical cysts; nd, not determined.
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showing an initial delay followed by an apparent recovery of
the wild-type export activity at longer time. Interestingly,
affected members of family MCKD#1, carrying the C317Y
mutation, seem to have a milder phenotype than patients in the
other families. This observation suggests a possible correlation
between genotype, cellular phenotype and clinical phenotype.
Mutant uromodulin transit through the ER is delayed
Since uromodulin mutations C148W, C150S, C315R and
C317Y affect disulfide bonds, we hypothesized the delayed
export to the plasma membrane to be caused by retention of the
protein in the ER due to the inability of the resident chaperones
to properly fold it. To test this hypothesis, we looked at the
intracellular distribution of wild-type and mutant uromodulin in
transfected HEK293 and HeLa cells at different times after
transfection.
Interestingly, a difference could be detected at early time-
lapses after transfection. In particular, at 4–8 h after transfec-
tion, wild-type cells showed a strong punctuate uromodulin
signal close to the nucleus that resembled a Golgi-like
distribution. On the contrary, mutant uromodulin gave a
reticular-like signal that was diffused throughout the cytoplasm
(Figs 8 and 9).
Colocalization experiments using Golgi (anti-golgin) and ER
(anti-calnexin) markers clearly demonstrated that mutant
uromodulin was mainly localized in the ER, whilst most
intracellular wild-type uromodulin was localized in the Golgi
compartment. Uromodulin signal in wild-type expressing cells
that were cultured in reducing conditions showed an intracel-
lular distribution very similar to that observed in cells
expressing the mutant constructs.
The different distribution was less clear by 24 h after
transfection probably reflecting the bias introduced by over-
expression of the protein. These experiments demonstrate that
uromodulin mutant isoforms show a delayed transit through the
ER, probably because of the inability to establish the
physiological disulfide bonds.
Immunopathology and electron microscopy
Normal kidneys were strongly positive to anti-uromodulin
antibodies at the thick ascending limb of Henle and at the distal
convolute (Fig. 10A and B). In both cases, uromodulin was
diffused in the cytoplasm with apical reinforce. Luminal cast
reactive to anti-uromodulin antibodies were frequently found,
while Bowman’s space was mostly negative with the exception
of a positive small area adherent to Bowman epithelia (not
shown). The pattern was markedly different in kidneys of
patients carrying uromodulin mutations, including GCKD. In
all cases, uromodulin signal was evident in the same tubule
segments, but the protein formed globular masses within
the cytoplasm (Fig. 10C–E). These intra-cytoplasm heaps were
confirmed by electron microscopy as fibrillar material mostly
evident in ER with smaller area overrunning mitochondria
(Fig. 10F).
Uromodulin urinary excretion is reduced
in MCKD patients
Urinary excretion of uromodulin was determined by western
blot analysis in family MCKD#1 carrying the mutation C317Y
(see below). Figure 11 shows that uromodulin was barely
detectable in urine of all the affected subjects carrying the
C317Y mutation including two young patients (III-4, III-5)
who still had a normal renal function. At variance, non-affected
subjects of the same pedigree had normal levels. Moreover,
analysis of 20 normal urines revealed fairly high levels in all
cases (data not shown).
DISCUSSION
This work demonstrates for the first time allelism between
MCKD/FJHN and GCKD due to uromodulin mutations and
shows new insights on the pathogenetic role of the mutant
proteins. So far, a GCKD variant associated with hypoplastic
kidneys and maturity-onset diabetes of the young has been
linked to mutations in the gene encoding the hepatocyte nuclear
factor (HNF)-1b (16). Also, HNF-1b mutations were recently
identified in patients with atypical FJHN, showing renal cysts,
renal developmental abnormalities and diabetes (20). The
GCKD family we studied differs from those carrying HNF-1b
mutations in that it shows association of glomerular cysts with
hyperuricemia, severe impairment of urine concentrating
capability and no evidence of diabetes (1). In all cases marked
aggregates of uromodulin in tubular cells were observed and
electron microscopy demonstrated accumulation of dense
Figure 2. Mutations in the UMOD gene. Top, control subject; bottom,
sequences from probands of each family. Affected individuals of family
MCKD#9 are heterozygous for the missense mutation C148W (444T>G);
C150S (449G>C) in family MCKD#7; C315R (943T>C) in family
GCKD#1; C317Y (950G>A) in family MCKD#1.
Table 2. Mutations in UMOD gene
Family Exon DNA changea Protein change
MCKD#1 5 nt950 G!A C317Y
MCKD#7 4 nt449 G!C C150S
MCKD#9 4 nt444 T!G C148W
GCKD#1 5 nt943 T!C C315R
aBase no. 1 corresponds to the first base of the translation start codon
(AC NM003361).
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fibrillar complexes within the ER. Transient transfections of
mutant UMOD constructs revealed a delay in the export of
mutant protein to the plasma membrane that is due to a retarded
transit of mutant protein through the ER. We hypothesize that
defective uromodulin trafficking due to protein misfolding is an
important factor in the pathogenesis of MCKD/FJHN and
GCKD.
Uromodulin contains a N-terminal signal peptide (the
cleavage site is most likely located between positions 23 and
24); three calcium binding epidermal growth factor (cbEGF)-
like domains between positions 31 and 148 and a fourth
potential cbEGF-like domain at position 281–336; a zona
pellucida (ZP) domain from amino acid 336 to 585 and a
glycosyl phosphatidylinositol (GPI) anchor attachment site at
position 614. EGF-like domains are widely distributed
throughout the animal kingdom and are almost invariably
found in a variety of secreted proteins or in the extracellular
domain of membrane-bound proteins. Their functional sig-
nificance is not yet clear. They contain six conserved cysteine
residues (C1–C6, respectively) that form disulfide bonds—
between C1 and C3, between C2 and C4, between C5 and
C6—that are important to establish the correct domain tertiary
structure (21). ZP domains are present in many extracellular
eukaryotic proteins including uromodulin, sperm receptors
ZP1 and ZP2, glycoprotein-2 (GP2), a- and b-tectorins and
transforming growth factor (TGF)-b receptor III. ZP modules
are involved in the polymerization of extracellular proteins into
filaments with a helical superstructure (22). ZP domain proteins
contain single transmembrane domains or GPI anchors that are
crucial for protein assembly and are missing in the secreted
mature proteins. ZP and probably the EGF-like domains are
important for uromodulin polymerization into the 10–15 nm
fibers observed by Wiggins (23).
Including the four new mutations reported in this study, 13
mutations in the uromodulin gene have been reported so far in
12 MCKD/FJHN and one GCKD families. Interestingly, 10
mutations are non-conservative substitutions affecting cysteine
residues and one is a glycine to cysteine change. Among the
reported UMOD mutations seven affect cysteine residues in
cbEGF-like domains II, III and IV. Furthermore, two additional
mutations localize to cbEGF-like domains and affect glycine
residue 103 (to cysteine), a change that probably affects
the disulfide bond pattern, and the conserved asparagine
residue 128, that is predicted to be part of the calcium
coordinating site (9).
Mutations affecting the disulfide bond pattern probably cause
domain misfolding with a damaging effect on the global
protein structure. The same effect can be hypothesized for
mutations that reduce the calcium-binding affinity since bound
calcium stabilizes the cbEGF-like domain conformation
restricting interdomain flexibility (24,25) and has a protective
role against proteolytic degradation (26). The effect of
uromodulin missense mutations that affect cysteine residues
150, 217 and 255 is more difficult to predict since they are
Figure 3. Multiple sequence alignment of human, dog, cow, mouse and rat uromodulin (GenBank AC NP_003352; AAO33163; NP_776638; NP_033496;
NP_058778; respectively). Conserved amino acids are shaded in gray. The 48 invariant cysteine residues are boxed. Cysteine residues that are affected by the four
missense mutations identified in this study (C148W, C150S, C315R and C317Y) are marked.
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localized in a protein region (residues 149–280) that
has no sequence similarity to any known protein domain.
Nevertheless, the strong conservation of this protein segment
among uromodulin homologs suggests that it is important for
protein function. Furthermore, since no free sulfydryl group
has been detected in uromodulin (18), these cysteine residues
are probably involved in intramolecular disulfide bond
formation, thereby contributing to protein folding.
In transfected cells that expressed uromodulin mutant
isoforms, the amount of protein exposed on the plasma
membrane was dramatically reduced. This difference was clear
at early times after transfection but became eventually
undetectable by 40–48 h after transfection when all the
transfected cells were very intensely labeled. This ‘saturation-
effect’ was observed both in HEK293 and HeLa cells and is
presumably due to the accumulation of uromodulin on the
plasma membrane as a consequence of the high expression rate
of transiently transfected wild-type and mutant constructs.
Even though we cannot exclude that some protein is eventually
released to the media, as shown in stably transfected HeLa cells
(27) and even assuming the existence in these cells of the not
yet identified specific protease activity that releases membrane-
anchored uromodulin from tubular cells (28,29), it is very
likely that the rate at which the protein is exported to the
plasma membrane overwhelms the one at which it is secreted.
By FACS experiments, we observed a significant reduction of
the number of uromodulin-exposing cells for mutants C148W,
C150S and C315R. However, when transfecting with the
C317Y isoform, the percentage of positive cells differed from
the wild-type only at early stages after transfection, while it
reached comparable values by 10 h after transfection. These
results suggest that there might be a difference in the extent to
which the different mutations affect uromodulin export
dynamics with mutation C150S being the most severe and
mutation C317Y being the least severe one. Interestingly, the
milder effect of mutation C317Y seems to correlate with
the milder phenotype of affected members of family MCKD#1
that carry the mutation.
Since the mutant isoforms are predicted to impair the proper
folding of uromodulin, we hypothesized the delayed export to
the plasma membrane to be due to a longer retention time in the
ER, where the proper set of disulfide bonds is formed by
resident disulfide isomerases. Indeed, at short times after
transfection, most wild-type uromodulin localized to the Golgi
apparatus while mutant isoforms mainly localized in the ER,
with little if any signal in the Golgi.
When transfected cells were cultured in reducing conditions,
wild-type uromodulin behaved very similarly to the mutant
isoforms and the extent of the maturation delay was
proportional to the concentration of the reducing agent.
Figure 4. Structure of uromodulin protein. Leader peptide is shown as a dotted box, cbEGF-like domains are displayed as numbered white boxes. Positions of the
ZP domain and the GPI-anchor attachment site are indicated. The seven glycosylation sites are marked as Y. The position and description of the 13 uromodulin
mutations that have been reported so far are shown. Mutations reported in this study are underlined; references to other studies are shown in brackets. The amino
acid sequence of cbEGF-like domains II, III and IV is shown (top line) aligned with the EGF-like consensus sequence (bottom line) from Pfam database (PF00008)
for domains II and III and SMART database (SM00181) for domain IV. Conserved residues and conservative substitutions are indicated (mid line). Disulfide bonds
C1–C3, C2–C4, C5–C6 for each cbEGF-like domain are shown as dotted lines and cysteine residues C1 to C6 are boxed. The position of uromodulin mutations
that hit residues belonging to EGF-like domains is marked with an asterisk.
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These results agree with previous studies that showed a reduced
maturation rate of uromodulin in stably transfected cells
cultured in reducing conditions (27) and substantiate the
evidence that the formation of the correct set of disulfide bonds
is the key step in uromodulin maturation that is affected by
C148W, C150S, C315R and C317Y mutations.
A similar effect of cysteine-affecting mutations on protein
maturation/export dynamics has been reported for other
proteins, such as fibrillin-1 whose cbEGF-like domains share
remarkable sequence homology to uromodulin ones. As
demonstrated (30), the replacement of cysteine residues within
fibrillin-1 cbEGF-like domain leads to a longer intracellular
retention.
The fate of misfolded proteins in the lumen of the ER is
thought to be retrotranslocation to the cytoplasm through a
translocon composed of Sec 61, ubiquitination and protea-
some-mediated degradation (31,32). In some pathologic
conditions, however, the mutant protein can form degrada-
tion-resistant aggresomes that are accumulated either in the ER
(33) or more often in the cytoplasm. Consistently, we showed
the presence of uromodulin positive globular aggregates within
the cytoplasm of tubular cells in kidney biopsies of MCKD/
FJHN and GCKD patients. EM findings, showing fibrillar
material mostly evident in ER, agree with the intracellular
distribution observed in cells that were transfected with
uromodulin mutant isoforms. Based on these results we
hypothesize that mutant uromodulin transit through the ER is
delayed and the protein eventually accumulates in the ER or
within the cytoplasm, possibly in compartments of ER origin.
Uromodulin aggregates could occur by either intermolecular
disulfide bonds or abnormal polymerization of the misfolded
protein.
Urinary excretion of uromodulin is dramatically reduced in
the affected members of family MCKD#1. The extent of the
reduction seems to exceed the expected one in the case of a
heterozygous mutation and suggests a possible dominant
negative effect. Possibly, the formation of intermolecular
disulfide bonds involving the spare cysteine residue of a
mutant molecule and its counterpart belonging to a wild-type
isoform, as shown for fibrillin-1 mutants (34), may support this
mechanism. However, the hypothesis of a dominant negative
effect of uromodulin mutants is not fully supported by
immunofluorescence and FACS experiments, which showed
an intermediate cellular phenotype in the simulated hetero-
zygous state. Nonetheless, we cannot exclude that a dominant
negative mechanism might require a long time to establish, i.e.
the ‘chronic’ expression of the mutant allele as opposed to the
‘acute’ one of transiently transfected cells. Also, uromodulin
overexpression and the use of cell types other than TAL tubular
cells could be further biases. Some of the clinical and
pathologic characteristics of patients with MCKD/FJHN and
GCKD such as low urine osmolality and tubulo-interstitial
fibrosis could be explained on the basis of the failure of
uromodulin function and the presence of intracellular/inter-
stitial mutant uromodulin deposits. A possible explanation of
the pathogenetic mechanisms leading to other features such as
the formation of medullary (MCKD) and cortical (GCKD)
cysts and hyperuricemia remains more difficult to establish.
There are some discrepancies in the literature regarding
uromodulin membrane distribution in the distal tubule cells.
Figure 5. Immunofluorescence localization of wild type and mutant uromodulin in transiently transfected cells. Rows A and B, transfected HEK293 cells; rows C
and D, transfected HeLa cells. Unpermeabilized cells were fixed in 4% PFA either 4 h (HEK293) or 6 h (HeLa) after transfection. Cells were cotransfected with an
EGFP expressing plasmid and either wild-type or mutant (C148W) uromodulin construct. Bar¼ 20mm.
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While most studies demonstrated uromodulin localization on the
apical plasma membrane of the TAL and DCT tubular cells
(10,11,35,36), few of them were able to show its presence on the
basolateral membrane of the TAL cells (11,36). Nevertheless,
uromodulin exclusive expression in epithelial cells of the TAL
and DCT is well established. It has also been shown that
uromodulin monomer can polymerize into 10–15 nm-wide fibers
that form a reversible gel-like structure (23) that is water
impermeable and allows ion movement (14). Taking into account
its localization and physicochemical properties and the electro-
lyte/water permeability of these nephron segments, it has been
proposed that uromodulin has a role in salt transport in the TAL
and DCT and water impermeability of the TAL, a process that is
crucial for urine concentration. Studies on rats fed with different
dietary salt load showed that uromodulin mRNA and protein
levels were increased in a high-salt diet. Furthermore, adminis-
tration of furosemide, a loop diuretic that binds to the Na–K–2Cl
cotransporter (NKCC2) in the thick ascending limb blocking ion
transport (37), further increased uromodulin mRNA levels in rats
on a high-salt diet (38). These results support the hypothesis of an
involvement, albeit secondary, of uromodulin in salt uptake in
the TAL. At the same time, failure of uromodulin to properly form
the water barrier that impermeabilizes the TAL could explain the
marked defect in the urine-concentrating process that determines
a constant and most typical low urine osmolality in patients
affected by these disorders.
A typical clinical feature of MCKD/FJHN patients also
present in family GCKD#1 is tubulo-interstitial fibrosis.
Although uromodulin has been implicated in urothelial defense
against infection (39), which may lead to fibrosis through
pathogen-induced local inflammation, it seems unlikely that the
tubulo-interstitial fibrosis of MCKD/FJHN and GCKD is due to
the lack of uromodulin protective role. In fact, urinary infections
are not increased in our MCKD/FJHN and GCKD patients.
Several observations have lead to the hypothesis that
uromodulin can also have an inflammatory potential (40) and
tubulo-interstitial nephritis in the TAL can be induced in rabbit
and rat following administration of uromodulin (41,42).
We hypothesize that tubular cells that are unable to degrade the
large amounts of misfolded mutant protein that is intracellularly
accumulated eventually go into apoptosis. Cell debris would
stimulate inflammation and fibroblast infiltration and would
release uromodulin aggregates in the interstitium that could in
turn induce an inflammatory response. Numerous studies
demonstrated the presence of interstitial deposits of uromodulin
in patients with tubulo-interstitial nephropathy, including
MCKD cases (43–45). Often uromodulin accumulation in the
interstitium is associated with infiltration of inflammatory cells
and this is considered a pathologic event in the kidney that
potentially triggers a pro-fibrotic cascade (43,44).
The cellular mechanisms leading to the formation of
medullary and glomerular cysts seem unexpected on the basis
of uromodulin function. Medullary cysts are not a common
feature in the MCKD patients we studied. Affected individuals
of family MCKD#9 had small kidneys without cysts and one
affected member only (II-3) of family MCKD#1 had medullary
cysts. The small cysts described in MCKD patients could arise
from tubule swelling. On the other hand, glomerular cysts are a
common clinical feature in the affected members of family
GCKD#1. They can occur as an isolated manifestation or be
associated with a variety of both glomerular and tubular
diseases including autosomal dominant and recessive poly-
cystic kidney and renal dysplasia or develop after an unrelated
glomerular disease, as in hemolytic uremic syndrome (46).
Figure 6. Uromodulin-positive membrane projections in unpermeabilized HEK293 (A) and HeLa (B) cells that were transfected with wild-type uromodulin. Cells
were fixed either 4 h (HEK293) or 6 h (HeLa) after transfection. Bar¼ 20 mm.
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Figure 7. FACS analysis of uromodulin-positive HEK293 cells transfected with either wild-type or mutant constructs. EGFP-expressing plasmid was used as a
transfection efficiency control. (A) Distributions of uromodulin positive cells at 14 h after transfection. (B) The number of uromodulin-positive cells is significantly
reduced for mutants C148W, C150S and C315R and for cells expressing wild-type uromodulin and cultured in reducing conditions (2 mM DTT). Cells were
collected 14 h after transfection. Uromodulin-positive cells were normalized by EGFP transfection. Average percentage values for six replicates are shown.
*P< 0.05; **P< 0.01 (Mann–Whitney two-tailed test). Bars represent  SD. (C) Time-course experiment showing the different export dynamics of mutant
C317Y as compared to mutant C148W and wild-type uromodulin. Cells were collected for FACS analysis at 6, 8 and 10 h after transfection. Bars represent  SD.
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A possible mechanism for glomerular cyst formation is tubular
obstruction that would lead to urine reflux and extravasation,
hence uromodulin interstitial deposits, and to an increased
pressure in Bowman’s space. Histochemical studies showing
the abnormal presence of uromodulin within glomerular cysts
support this possibility (44).
Along with a defect in the concentrating capability,
hyperuricemia seems to be a common feature in all the families
with UMOD mutations that have been reported so far. The
overall tubular reabsorption of urate in humans is a complex
phenomenon based on a balance between true reabsorption,
secretion and post-secretion reabsorption. All these phases
should be confined to the proximal tubule (47) where the
human urate transporters URAT1 and hUAT are endowed
(48,49). We hypothesize that hyperuricemia in MCKD/FJHN
and GCKD patients is secondary to volume contraction. This
may result from a reduced NaCl reabsorption in the TAL due to
loss of water impermeability as a consequence of intracellular
accumulation of mutant uromodulin. The decreased Naþ
uptake in the TAL would be compensated by enhanced Naþ
reabsorption in the proximal tubule thus increasing the activity
of the urate transporter URAT1 (49).
It seems interesting to note that some patients of
family MCKD#7 presented with either hyperuricemia or
cortico-medullary cysts with or without uremia (see Table 1).
The possible activity of modifier genes that could explain the
interfamilial variability should be taken into account.
In conclusion, we have shown that mutations in the
uromodulin gene are causative of different disorders such as
MCKD/FJHN and GCKD. Clinical features common to all
patients were the presence of tubulo-interstitial fibrosis,
reduced urinary concentrating ability and, except in few
cases, hyperuricemia. Interestingly, the vast majority of
uromodulin mutations reported so far are likely to affect the
protein folding. Consistently, we have provided evidences that
uromodulin mutations affect the protein intracellular traffick-
ing delaying its transit through the ER with chronic effect that
discloses a functional/molecular/clinical correlation. This
Figure 8. Intracellular localization: uromodulin and golgin staining. Permeabilized
HEK293 cells were transfected, fixed 6 h after transfection and incubated with anti-
uromodulin and anti-golgin (Golgi marker). Wild-type uromodulin is mainly loca-
lized to the Golgi apparatus. Bar¼ 16mm.
Figure 9. Intracellular localization: uromodulin and calnexin staining.
Permeabilized HEK293 cells were transfected with either wild-type or mutant
constructs, fixed 6 h after transfection and incubated with anti-uromodulin
and anti-calnexin (ER marker). Mutant uromodulin mainly localizes to the
ER. Wild-type uromodulin in cells cultured in reducing conditions shows the
same localization pattern of mutant isoforms. Bar¼ 16 mm.
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eventually results in intracellular accumulation of uromodulin
aggregates in tubular epithelial cells and significant
reduction of secreted protein in patient urine. Further
studies are required to elucidate the mechanisms through
which intra- and extracellular deposits of uromodulin exert
their renal toxicity.
Figure 10. Intracellular aggregates of mutant uromodulin in epithelial cells of TAL and DCT. Kidney biopsy sections of control and patients are shown. (A, B)
uromodulin staining in control biopsy, showing a diffuse cytoplasmic staining with apical reinforce (100). (C, D) patient IV-6 of family MCKD#1 (E) patient IV-1
of family GCKD#1 (100). In both patient biopsies uromodulin intracellular aggregates are evident. (F) Transmission electron microscopy of kidney biopsy from
patient IV-6 of family MCKD#1 showing abnormal fibrillar material mostly evident in the ER (5700).
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MATERIALS AND METHODS
Patients
Families were investigated on the basis of a MCKD/FJHN
clinical picture as defined by the following criteria: (a) history of
renal insufficiency with inheritance compatible with an autosomal
dominant trait; (b) stable low urinary osmolality in the first
morning urine and lack of any compensatory effect after
endonasal Minirin (two pushes); (c) history of gout and
hyperuricemia (serum uric acid >6 mg%) due to low fractional
excretion of uric acid (<5%). In the absence of a clear history of
gout, hyperuricemia was defined as a serum level of uric acid
higher than one standard deviation of the normal values for age
and sex; (d) renal biopsy showing tubulo-interstitial fibrosis with
infiltrates, tubular atrophy and thickening of the tubular basal
membrane with periodic acid Schiff-positive material. The family
with GCKD included three patients in two generations that
presented the above clinical features except point d. In particular,
all presented mild polyuria associated with low urine density
(<400 mOsm H2O/kg), slight increment of serum creatinine,
hyperuricemia with decreased excretion fraction according to the
enrolment criteria. Renal histology was characterized by marked
dilation of Bowman’s spaces affecting 40% of more than 100
glomeruli, with reduced or rudimentary glomerular tufts. Diffuse
and mild interstitial fibrosis was observed.
Mutation screening
We isolated the genomic sequences spanning the UMOD gene
from a phage human fibroblast genomic library (CAT 946204,
Stratagene, La Jolla, CA, USA) using a 609 bp fragment of
UMOD cDNA (GenBank M15881; nt pos. 147–756) as a probe.
Intron–exon boundary sequences were determined by direct
automated sequencing (ABI-PRISM 310 Genetic Analyzer,
Applied Biosystems, Foster City, CA, USA) of lambda clones.
PCR primers for the specific amplification of UMOD 12 exons
(including non-coding exons 1 and 2) and intron/exon borders
were designed using the Primer Express program (Applied
Biosystems). Primer sequences are available upon request.
Mutation analysis was performed by direct sequencing of
PCR products. Each exon was amplified from patient genomic
DNA, purified (PCR Product Pre-Sequencing kit, USB,
Cleveland, OH, USA) and sequenced using the BIG DYE
dideoxy-terminator chemistry (Applied Biosystems) on an ABI
3100 DNA sequencer (Applied Biosystems). Chromas 1.5
software (Technelysium, Helensvale, Qld, Australia) and
LASERGENE package computer programs (DNASTAR,
Madison, WI, USA) were used to edit, assemble and translate
sequences. Mutation analysis was performed on two affected
individuals from each MCKD/FJHN and GCKD family.
Co-segregation analysis of mutations and mutation screening
in 100 unrelated controls was performed by direct sequencing.
The conservation of the mutated amino acid residues was
assessed by BlastP alignment of human wild-type protein and
other mammalian uromodulin homologs (Bos taurus, Canis
familiaris, Rattus norvegicus, Mus musculus). Protein pattern
identification was performed by PIX analysis (www.hgmp.mrc.
ac.uk), by Pfam analysis (www.sanger.ac.uk) and by using the
ExPASy Proteomics tools (www.expasy.ch).
Immunopathology and electron microscopy
Immunopathology was performed on normal portions of
kidneys removed for renal carcinoma, as well as on renal
biopsies from patients IV-6 (family MCKD#1) and IV-1 (family
Figure 11. Uromodulin excretion is reduced in patients of family MCKD#1. Western blot of total urine proteins was labeled with anti-uromodulin antibody.
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GCKD#1). Tissues were fixed in paraformaldehyde and
embedded in paraffin. Sections of 3 mm thickness were first
treated with microwaves for three cycles of 5 min each and then
incubated with monoclonal anti-uromodulin antibodies (1032A
clone; Cedarlane, Hornby, Ontario, Canada) diluted 1 : 32 000
and 1 : 1 000 000, for 30 min. After several washings in PBS,
a goat anti-mouse IgG linked to biotin was incubated for
further 30 min with gentle agitation. Staining was developed
with streptavidin peroxidase for 15 min and diaminobenzidin.
For transmission electron microscopy tissues were fixed in
2.5% glutaraldehyde phosphate buffer 0.1M (pH 7.2) for 3 h,
post-fixed in 1% osmium tetroxide, dehydrated in alcohol and
propylene oxide and then embedded in Epon 100. Semi-thin
sections (0.5 mm) were stained with methylene blue and
saphranine and inspected under microscope to cut regions for
ultra-thin sections. Ultra-thin sections were stained with uranyl
acetate and lead citrate, and subsequently mounted on copper
grids. They were analyzed with a Philips EM 301 electron
microscope at 60 kV.
Uromodulin expression constructs and
site-directed mutagenesis
We derived uromodulin full-length cDNA by RT–PCR on human
kidney cDNA (MTC panel, BD Biosciences Clontech, Palo Alto,
CA, USA) using primers: forward 50-CCCAAGCTTACAAG
TAGCGGGAAGAGCAGAAAGG-30 (HindIII tail); reverse
50-CGGAATTCATAGGGAGAAAAGAAGGCAGGC-30 (EcoRI
tail). The PCR product was gel purified and cloned into the
expression vector pcDNA3.1 (Invitrogen). We mutated uromo-
dulin cDNA by using the QuickChange site-directed mutagenesis
kit (Stratagene). We introduced the four mutations identified
in MCKD/FJHN and GCKD patients: 444T>G (codon
TGT>TGG, C148W); 449G>C (TGC>TCC, C150S);
943T>C (TGC>CGC, C315R); 950G>A (TGC>TAC,
C317Y). The primer pairs used for site-directed mutagenesis are
(50 to 30): C148mutf, GGATGGATGGCACTGGGAGTGCT
CCCCGGG; C148mutr, CCCGGGGAGCACTCCCAGTGCC
ATCCATCC; C150mutf, GATGGCACTGTGAGTCCTCCCC
GGGCTCCTG; C150mutr, CAGGAGCCCGGGGAGGACT
CACAGTGCCATC; C315mutf, AATGGCAGATGGCACCG
CCAGTGCAAACAGG; C315mutr, CCTGTTTGCACTGGC
GGTGCCATCTGCCATT; C317mutf, GATGGCACTGCCAG
TACAAACAGGACTTCAAC; C317mutr, GTTGAAGTCCT
GTTTGTACTGGCAGTGCCATC. Constructs were fully
re-sequenced.
Western blot
Transfection was carried out by using Metafectene (Biontex,
Munich, Germany) according to the manufacturer’s instruc-
tions. We used 1 mg of plasmid DNA for 2.6 106 cells. We
changed media 2 h after transfection and let cells grow for 12 h.
Cells were collected in Versene (Invitrogen) and lysed in 1%
NP-40 (Nonidet P-40 detergent, Sigma-Aldrich, St Louis, MO,
USA), 50 mM Tris pH 7.5, 150 mM NaCl. Proteins were
quantified by using the Bio-Rad Protein Assay (Bio-Rad,
Hercules, CA, USA). We loaded equal amounts of proteins
(70 mg) on reducing SDS–PAGE. We incubated transblotted
nitrocellulose membranes with goat polyclonal antibody
against uromodulin (ICN Biomedicals, Irvine, CA, USA;
1 : 1000 dilution) followed by incubation with horseradish
peroxidase-conjugated secondary antibody (Promega,
Madison, WI, USA; 1 : 2000 dilution). Protein bands were
visualized with the Enhanced Chemiluminescence kit
(Amersham Biosciences, Piscataway, NJ, USA).
Twenty four-hour urine collections were obtained from
affected and non-affected members of family MCKD#1 and
maintained in timole. MCKD#1 patients showed a mild polyuria
with a urinary volume ranging from 1400 to 2000 ml/24 h. After
centrifugation of 100 ml urine at 1000 g, supernatants were first
dialyzed against water for 24 h with several changes and then
lyophilized. Since proteinuria was below the normal range of
excretion (<150 mg/24 h) in affected and non-affected mem-
bers, equal amounts of proteins (50 mg) were loaded to the gel
track and separated on SDS–PAGE.
Immunofluorescence experiments
Cells were grown for 16 h prior to transfection on glass cover
slips in 12-well plates (Corning Life Sciences). Transfections
were carried out as above using 500 ng of plasmid DNA for 106
cells. Heterozygotes were simulated by cotransfecting equal
amounts (250 ng) of wild-type and mutant plasmid DNA.
Transfection efficiency was determined by cotransfecting with
enhanced green fluorescent protein (EGFP) expressing vector
pcDNA3x(þ)MyEGFP (Invitrogen). Fresh media was added
2 h after transfection. For cells cultured in reducing conditions,
added media contained 2 mM DTT. Cells were fixed at different
times after transfection (4, 6, 8, 12, 20, 40, 48, 50 and 74 h)
either in 4% PFA for 30 min at 37C (unpermeabilized cells) or
in 100% methanol for 5 min at 20C (permeabilized cells).
Unpermeabilized and permeabilized cells were incubated
with pre-immune donkey serum for 30 min at 37C. Cells
were then incubated with goat polyclonal primary antibody
against uromodulin (ICN Biomedicals; 1 : 500 dilution).
Permeabilized cells were also stained using sheep anti-golgin
(Molecular Probes, Eugene, OR, USA; 1 : 300; Golgi marker)
and sheep anti-calnexin (Sigma-Aldrich; 1 : 500; ER marker).
We washed cells in phosphate-buffered saline solution and
incubated with appropriate secondary antibodies (1 : 1000):
AlexaFluor 594-conjugated donkey secondary antibody against
goat IgG (Molecular Probes); AlexaFluor 488-conjugated
donkey secondary antibody against sheep IgG (Molecular
Probes). We placed cells in fluorescent mounting medium
(DakoCytomation, Glostrup, Denmark) over microscope slides
and visualized them under confocal microscope Leica TCS SP2
AOBS (Leica Microsystems, Bannockburn, IL, USA).
Cell sorting experiments
Transfections were carried out as above (see western blot
section). Cells were collected in Versene (Invitrogen) at 6, 8 and
10 h after transfection and resuspended in aMEM þ FBS 2%
(2.4 106 cells/ml). Cells were incubated with polyclonal
antibody anti-uromodulin (ICN Biomedicals; 1 : 1000/
700 000 cells) for 30 min at 4C and washed with
aMEM þ FBS 2%. Cells were incubated for 30 min at 4C
with the secondary antibody: polyclonal donkey anti goat Alexa
488 conjugated (1 : 2500/700 000 cells; Molecular Probes).
3382 Human Molecular Genetics, 2003, Vol. 12, No. 24
 at U
niversita of Brescia on O
ctober 23, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Cells were washed with aMEM þ FBS 2%, resuspended in
300 ml of aMEM þ FBS 2% and incubated 10 min at RTwith 7-
amino-actinomycin D (7AAD) for the exclusion of nonviable
cells. Cell fluorescence was measured by flow cytometry
(FACSCalibur, BD Biosciences) and analyzed by CellQUEST
software (BD Biosciences).
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